Introduction
Progressive myoclonic epilepsy (PME) is a group of disorders in which myoclonus is a major component. Patients with PME typically have generalized tonic-clonic or clonic seizures, mental retardation culminating in dementia, and a neurologic syndrome that almost always includes cerebellar dysfunction. It comprises a heterogeneous group of inherited disorders. 1, 2 Conditions in which PME is seen include Unverricht-Lundborg disease, sialidosis, Gaucher's disease, mitochondrial encephalomyelopathy with ragged-red fibers (MERRF), Lafora's disease, neuronal ceroid lipofuscinosis, and Dentato-Rubro-Pallido Luysian Atrophy (DRPLA). The intensity of the various clinical features varies depending on the etiology. Although valproate, benzodiazepines, piracetam, zonisamide, topiramate, and levetiracetam have had a positive impact on the control of the epilepsy, the prognosis of this syndrome is poor. 3 PME is also not responsive to open surgical resection. Among complimentary treatment options for epilepsy resistant to medical and open surgical treatments, most patients so far have been treated by vagus nerve stimulation (VNS). 4, 5 VNS is a widely used neurostimulation for treatment-resistant epilepsy. Its components are a pulse generator and a bipolar vagus nerve lead. The generator is designed to be implanted in the patient's chest on the upper left side. This pulse generator produces charge-balanced waveforms at a constant current. The effectiveness of VNS for PME has rarely been reported. 6 The purpose of this study was to evaluate the efficacy of VNS for PME.
Patients and methods
All the investigations and treatments were evaluated and approved by the ethics committee at Seirei Hamamatsu General Hospital.
Patient1
A 16-year-old, right hand-dominant man visited our hospital with bilateral hand myoclonus, epileptic seizures, cerebellar symptoms, and mild mental impairment. He had exhibited myoclonus and epileptic seizures since 12 years of age. These symptoms gradually worsened. The seizure frequency and intensity also deteriorated and occasionally progressed to status epilepticus. This condition was diagnosed as PME based on the presence of EEG abnormalities, myoclonus, and mental retardation. Muscle biopsy and genetic studies showed mitochondrial encephalomyelopathy with ragged-red fibers (MERRF). He used to be on valproate, clonazepam, and topiramate, but he developed valproate-induced acute pancreatitis. Currently, he had been on levetiracetam 3000 mg/day, clonazepam 1.5 mg/day, and topiramate 300 mg/day. The seizure frequency was weekly. Status epilepticus occurred once to twice a year. He was basically wheelchair bound, walking occasionally with assists. He had intentional and resting tremor and truncal ataxia.
EEG showed diffuse 6-7 Hz theta activities. There were frequent generalized poly-spike-waves. Photic stimulation induced bilateral hand and eyelid myoclonus with generalized polyspike-wave activities. MRI showed an atrophic brain stem and cerebellum.
VNS (VNS therapy system, Cyberonics, Inc., Houston, TX, USA) was performed for this patient.
Patient 2
A 20-year-old woman was referred from a nearby hospital. She was diagnosed as having Gaucher's disease type III based on genetic and other studies. Gaucher cells were found in her bone marrow. Blood sampling showed deficient glucosylceramidase enzyme activity. Her sibling was also diagnosed as having the same disease. She started exhibiting myoclonus involving her hands and generalized seizures at the age of 13 years. Her seizure frequency and intensity had deteriorated gradually, becoming daily by 18 years of age. She also suffered from status epilepticus monthly. Although she had cerebellar symptoms, she was able to walk by herself with spasticity. She was on valproate 600 mg/day, clonazepam 1.5 mg/day, and topiramate 400 mg/day. She was also on enzyme replacement therapy and chaperone therapy.
EEG showed posterior dominant, 7-8 Hz alpha and theta activities. There were frequent high-amplitude, generalized, poly-spike-waves, especially with photic stimulation. This EEG was suggestive of encephalopathy and generalized epilepsy. MRI showed a diffuse atrophic brain for her age.
VNS was performed for this patient.
Results
Patient 1: Postoperatively, the patient did not show any complications, including hoarseness, infection, or cardiac issues. The VNS initial dosing 2 weeks after the VNS implant was: output current, 0.25 mA; on time, 30 s/off time, 5 min; signal frequency, 30 Hz; and pulse width, 500 ms. The patient visited our outpatient office every 4-5 weeks until visit 5. The dosing increment was 0.25-1.25 mA. He became free of seizures 4 months after the VNS implant. During 1 year and 8 months of follow-up, he has not exhibited epileptic seizures and status epilepticus. His mental retardation, myoclonus, and cerebellar symptoms have shown no marked changes after the VNS; VNS improved only the epileptic seizures (Table 1) .
Patient 2: Postoperatively, the patient did not show any complications, including hoarseness, infection, or cardiac issues. The VNS initial dosing 2 weeks after the VNS implant was: output current, 0.25 mA; on time, 30 s/off time, 5 min; signal frequency, 30 Hz; and pulse width, 500 ms. The patient visited our outpatient office every 4-5 weeks.
The dosing increment was 0.25-1.5 mA. Her seizure frequency reduced gradually. She had status epilepticus 4 months after the VNS implant, after which she has not showed status epilepticus. During 1 year and 6 months of follow-up, she has been free from epileptic seizures. Her mental retardation and cerebellar symptoms have shown no marked changes after VNS. She continues to have severe hand myoclonus even after VNS. (Table 1) 
Discussion
Current treatment for PME mostly relies on a combination of valproate and benzodiazepines, usually clonazepam. 7 Zonisamide is considered a major antimyoclonic agent. 8 Topiramate also seems to have a specific antimyoclonic effect. 9 Levetiracetam has proven efficacy for photo-sensitive seizures. 10 However, the results for PME have been disappointing. VNS was performed for two patients with PME. The VNS has achieved seizure freedom and been effective for status epilepticus in these two patients throughout more than 1 year of follow-up.
There have been two previous reports on PME treated with VNS. Thus, including the present cases, there have been four patients with PME who underwent VNS (Table 1) , including one with Unverricht-Lundborg disease (ULD), one with MERRF, one with Gaucher's disease Type III, and one that remains unclassified. VNS improved generalized seizures in all four patients. Of these four patients, two had status epilepticus. Thus, VNS is effective for status epilepticus. Although VNS improved myoclonus and cerebellar dysfunction only in Smith's patient, the present patients and Vesper's patient did not respond to VNS with respect to myoclonus, cerebellar symptoms, and mental retardation. Since PME is a progressive disorder, the efficacy of VNS might decrease over time. Two of the four patients showed deterioration in myoclonus. We regard this as part of the progressive disease, and not a result of VNS. Wille 11 reported five patients with PME who underwent subthalamic deep brain stimulation (DBS) system implantation. DBS has been effective in myoclonus. One patient 12 has been seizure-free with VNS and myoclonus reduction with DBS. However, an increase in stimulation amplitudes provoked worsening of epileptic activity or considerable side effects in all but one of five patients. VNS seems to show efficacy for ULS, MERFF, and Gaucher's disease. The effect of VNS might not differ by PME etiology. VNS reduced generalized seizures and status epilepticus in patients with PME. However, the efficacy of VNS for myoclonus, mental retardation, and cerebellar symptoms remains unclear.
Conclusion
VNS is useful for epileptic seizures and status epilepticus in patients with PMEs. However, VNS might not control myoclonus, cerebellar symptoms, and mental retardation in some patients. Epileptic seizures and status epilepticus reduce PME patients' quality of life. VNS can be a treatment option for medically intractable epilepsy in PME patients. Further studies with a larger number of patients and longer follow-up periods are needed. 
